An interventional study of Pharmacist-led Cognitive Behavioral therapy and Basic Education in Diabete Mellitus, sponsored by Hamdard University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Hamdard University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Diabetes Mellitus with a site in Pakistan — 23 open to participants now, 28 under way, 2 of them phase 3. Diabetes Mellitus · Pakistan.
Among the 77 studies in Diabetes Mellitus with a site in Pakistan, this one is the 5th largest by planned enrollment of the 63 interventional ones that give a count, is one of 12 that started in 2025, is one of 52 with no phase, reaches primary completion later than 11 of the 27 other live ones, and was the 50th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →23 of the 77 studies in Diabetes Mellitus with a site in Pakistan are open now. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages up to 18
University of Faisalabad · Sites in Pakistan
Ages 40–60
Nabiqasim Industries (Pvt) Ltd · Sites in Pakistan
Ages 18–80
University of Lahore · Sites in Pakistan
Ages 18+
Khyber Medical University Peshawar · Sites in Pakistan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 25 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 4 · Phase 4 3
First in 2004; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 385 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 100 across the 63 interventional studies, 300 across the 13 observational. Of the 40 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 77 have an industry lead sponsor. The 10 most frequent:
Hamdard University is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Hamdard University has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
6 of the studies in Diabetes Mellitus with a site in Pakistan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073768Phase 3Khyber Medical College, PeshawarComparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients | 2026-12-26 |
| NCT06561126Khyber Medical University PeshawarEngagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D] | 2026-11-30 |
| NCT07425275Khyber Medical University PeshawarIntegrated Oral Care Intervention for Xerostomia in Diabetes Patients | 2026-12-25 |
| NCT07378293Shaheed Benazir Bhutto University Sheringal Dir UpperEffects of Selected Statins on Blood Glucose Levels in Healthy Volunteers | 2026-12-30 |
| NCT07109895University of LahoreCustom Insole With Transcutaneous Electrical Nerve Stimulation on Clinical Outcomes of Diabetic Foot Ulcers | 2026-12-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 77 studies in Diabetes Mellitus with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This interventional study will to assess the impact of pharmacist-led educational intervention along with cognitive behavioral intervention in diabetic patients. Participants of this study will be provided regular counselling or cognitive behavioral intervention and educational material as part of their routine pharmacy visit. Researchers will compare the two groups to see which of the two groups improve in term of medication adherence and quality of life.
The purpose of the study is to investigate whether incorporating pharmacist-led educational interventions along with Cognitive Behavioral Therapy (CBT) can result in better outcomes for diabetic patients. Effective diabetes management requires proper education and adherence to medication. Missed doses or irregular medication use can lead to poor glycemic control and increased complications. The study will examine if educational interventions along with Cognitive Behavioral Therapy (CBT) can have a favorable effect on various aspects of diabetes management coping techniques, Medication beliefs, reduction in hypo and hyperglycemic frequency, HbA1c and medication related problems (MRPs) medication adherence and overall quality of life of diabetic patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All confirmed Type II diabetic patients who visit endocrinology OPD Clinic during study duration.
Patients having >8%. Follow up as well as new patients were included subjects willing to participate in the study with or without other severe co-morbidities were included in the study.
Exclusion Criteria:
GDM diabetic patients Patients with Central Obesity Type I DM Patients Patients with inadequate medical history Patient having \<8% Patient who are not interested in the study are excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine healthcare practices and protocols for diabetes management. Regular advice on medication, diet, and lifestyle modifications in accordance with established guidelines, Follows conventional approaches. Lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.
Other: Basic Education
Specific Patient-centered strategies beyond routine care designed to address individualized needs. Customized interventions, including pharmacist-led educational sessions, personalized counseling, or advanced lifestyle modifications. Aims to enhance patient outcomes by providing tailored and innovative solutions for better diabetes management. Change in lifestyle / link with any daily activity (Yoga and Meditation Specifically guide about food portions and how to balance each food group in daily routine along with recommended daily physical activity type and duration. Pill planner will also be provided to this group. Medication counselling, Insulin technique, Dose Adjustment, Titration, Insulin Correction. Cognitive Behavioral Therapy will be provided.
Behavioral: Pharmacist-led Cognitive Behavioral therapy
Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
Basic Education about lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.
Medication adherence score
Adherence will be assessed using (Medication Adherence Reporting Scale) MARS-10. This scale describes three-dimension, Medication adherence behavior (1-4), attitude towards taking medication (5-8), negative side effects and attitudes to psychotropic medication (9-10). Each question has Yes and No response, a response consistent with adherence is coded as 1 and with non-adherence coded as 0. Higher the score higher will be the adherence. Adherence \<6 is poor adherence, and \>8 is high adherence.
Time frame: 3 months
Quality of life Score
Patient's quality of life will be assessed using Revised Version of DQOL (RV-DQOL13 ; Audit of diabetes dependent quality of life) will be used to access the quality of life of the patient. Its scoring ranges from 1- 100
Time frame: 3 months
Incidence of Drug-Drug Interactions
Drug interactions among oral anti glycemic and other drugs will be assessed using standard website (update-Lexicomp) It is used to access the reduction in no. of drug drug interaction after pharmacist intervention in both control and Cognitive Behavioral Intervention groups.
Time frame: 3 months
HbA1c %
HbA1c levels (%) will be assessed before the intervention is provided and after 3 months.
Time frame: 3 months
Plan to share: Undecided — The sharing will be dependent on the consent provided by the patient.
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Jul 2025, 5 months later.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamdard University